Compare Inovio Pharmaceuticals Inc (INO) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Vanguard Mega Cap Growth ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Vanguard Mega Cap Growth ETF trades at $90.18. The key difference: Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | MGK | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $2.87 | $92.06 |
52-Week Low | $0.66 | $70.70 |
Enterprise Value | $49.56M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
MGK trades at $90.30, down 0.36% on the day, with technical indicators showing a bullish trend supported by moving averages but overbought RSI readings. The ETF maintains strong institutional interest, with Bay Colony Advisory Group increasing its stake by 378.7% in the latest quarter. Recent news highlights MGK's superior five-year returns compared to small-cap alternatives, though with higher volatility due to its concentrated mega-cap tech focus.
MGK offers exposure to large-cap growth stocks with a low 0.05% expense ratio, delivering strong historical performance but facing concentration risk in technology sectors. The ETF's outlook remains positive given its track record of beating the S&P 500, though investors should monitor tech sector volatility and potential valuation pressures in mega-cap names.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
